<DOC>
	<DOCNO>NCT00656799</DOCNO>
	<brief_summary>The clinical trial objective evaluate dialysability sugammadex-rocuronium complex ; 's safety efficacy participant severe renal impairment .</brief_summary>
	<brief_title>Dialysis Sugammadex Participants With Severe Renal Impairment ( Study 19.4.333 ) ( P05773 )</brief_title>
	<detailed_description>The current trial design evaluate dialysability sugammadex-rocuronium complex participant severe renal impairment . A dose 4.0 mg/kg sugammadex administer 15 minute administration 0.6 mg/kg rocuronium . Blood dialysate sample collect , hemodialysis/filtration , calculation clearance sugammadex-rocuronium complex assessment rebound .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>At least 18 year age American Society Anesthesiologists ( ASA ) Class &gt; =4 Creatinine clearance ( CLCR ) &lt; 30 mL/min clinical indication dialysis Hospitalization Intensive Care Unit ( ICU ) schedule ( surgical ) procedure general anesthesia require neuromuscular relaxation use rocuronium Scheduled ( surgical ) procedure supine position Written informed consent ( legal representative ) Known suspect neuromuscular disorder impair neuromuscular blockade and/or significant hepatic dysfunction Known suspect ( family ) history malignant hyperthermia Known suspect allergy narcotic , muscle relaxant medication use general anesthesia Have already participate sugammadex trial Have participate another clinical trial , preapproved NV Organon , within 30 day study entry Females pregnant* Females breastfeed * In female pregnancy exclude medical history human chorionic gonadotropin ( hCG ) test within 24 hour surgery except female childbearing potential , i.e . least 2 year menopausal undergone tubal ligation hysterectomy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>